Thelansis

Non-Valvular Atrial Fibrillation (NVAF) Market Outlook Thelansis’s “Non-Valvular Atrial Fibrillation (NVAF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Valvular Atrial Fibrillation (NVAF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have...

  Non-Valvular Atrial Fibrillation (NVAF) Market Outlook Thelansis’s “Non-Valvular Atrial Fibrillation (NVAF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Valvular Atrial Fibrillation (NVAF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Non-Valvular Atrial Fibrillation (NVAF) Overview Valvular atrial fibrillation (AF) is a condition where AF occurs in the presence of mitral stenosis or mechanical valve prosthesis. On the other hand, non-valvular atrial fibrillation (NVAF) refers to an irregular and often rapid heartbeat in the heart’s atria. However, unlike valvular AF, it is not associated with significant heart valve...